Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A phase 1/2 trial of Venetoclax and Azacitidine in myelodysplastic syndromes / neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Aptose Biosciences Inc., now recruiting.
Overview
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT03850574 by Aptose Biosciences Inc., with 240 participants planned, started 2019-03-11 and due to reach its primary completion in 2026-11. Interventions recorded: Tuspetinib, Venetoclax Oral Tablet and Azacitidine for Intravenous Infusion.
Similar pages
not linked directly; found by shared links- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialRoll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.